JPS5938206B2 - Bronchial asthma treatment whose main ingredient is coenzyme Q - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a therapeutic agent for bronchial asthma containing coenzyme Q represented by the following general formula (%) as a main component.

Coenzyme Q was discovered by Crane in 1957 from the mitochondrial lipids of cow heart.

In nature, coenzyme Q exists with various numbers of n in the above general formula.

Although its action in vivo is not fully known, it is thought to be involved in the electron transport system.

As for the medical use of coenzyme Q, coenzyme QIO is currently used as a therapeutic agent for depressive heart failure.

The present inventor has discovered that this coenzyme Q is effective as a therapeutic agent for bronchial asthma.

Bronchodilators are usually used to treat bronchial asthma, but coenzyme Q was further administered to patients whose symptoms did not improve even with the administration of bronchodilators.
A clear improvement in symptoms was observed.

The dosage of coenzyme Q in the present invention is about 5 ml per day for an adult.
The rI is 17-200.

The dosage form may be oral or injection, and the dosage form may be any form such as powder, granules, tablets, capsules, and injections.

These can be produced by conventional methods using conventional excipients.

Coenzyme Q is a highly safe substance, and its acute and chronic toxicity is as follows.

O Acute toxicity (+729/?) Coenzyme QIO administration 0 Chronic toxicity Coenzyme QIO administered to male and female Wistar rats 6.60°6
00m! I'/ was given 51'/day by force for 26 consecutive weeks, and no differences were observed from the control group in general conditions, fluid extraction, urinalysis, and morphological observation (macroscopic and histological). .

EXAMPLES Next, the present invention will be explained in more detail with reference to Examples.

Example 1 Treatment of bronchial asthma patients by administration of coenzyme Q1o A patient who is a bronchial asthma patient who is receiving a bronchodilator as a therapeutic agent, and whose symptoms have hardly changed over the past month or so, and no improvement trend has been observed. In 24 cases, additional coenzyme QIO
was administered.

The dosage of coenzyme Qto was 30~ per day, divided into 3 times after meals, and orally administered for 4 weeks.

20 points for no asthma symptoms during the day, 1 point for mild asthma with shortness of breath, 3 points for mild attack, 26 points for moderate attack,
Severe attack: 9 points, and the total score for one week is considered the severity for one week, one week before coenzyme QIO administration and 1.2 after administration.
, 3.4-week severity was determined.

Those whose severity decreased by 5 or more points 4 weeks after administration compared to 1 week before administration: markedly effective; those whose severity decreased by 3 to 4 points: effective.
The therapeutic effect of coenzyme QIO was determined as 1 to 2 point decrease: somewhat effective, no change in score, and conversely increase in score: ineffective.

Examples of patients and treatment results are shown below.

As shown in the table above, the treatment results for 24 patients with bronchial asthma were excellent in 9 cases, effective in 8 cases, moderately effective in 3 cases, and ineffective in 4 cases, and the treatment was effective in 20 out of 24 cases. (about 83
%).

Therefore, coenzyme Q.

It is clear that the drug is excellent as a treatment for bronchial asthma.

Example 2 Capsule Coenzyme QI0 5g Microcrystalline cellulose 80g Corn starch 20g Lactose
22g polyvinylpyrrolidone 3g total
Amount: 130g The above ingredients were granulated using a conventional method, and then filled into hard gelatin capsules.
Coenzyme Q1o 5772? It was made into a capsule containing.

Example 3 Powder coenzyme Q1o 50g Microcrystalline cellulose 400g Corn starch 550g total
Amount: 1,001 Coenzyme QIO was dissolved in acetone, then adsorbed onto microcrystalline cellulose, and then dried.

This was mixed with corn starch and made into a powder using a conventional method.

Example 4 tablet Coenzyme Q□.

5g corn starch 10g refined white sugar
20g carboxymethyl cellulose calcium 10g microcrystalline cellulose
40g polyvinylpyrrolidone
5g talc
10g total amount 10
0 g of coenzyme QIO was dissolved in acetone, then adsorbed onto microcrystalline cellulose, and then dried.

This cornstarch, refined sucrose, and carboxydimethylcellulose calcium were mixed, and then an aqueous solution of polyvinylpyrrolidone was added as a binder and granulated by a conventional method.

After mixing this with talc as a lubricant, 1 tablet
00~ (containing coenzyme Q105~) was compressed into tablets.

Example 5 Injection coenzyme Q1o10g Nikkol HCO-60 (trademark, Nikkol Chemiriki 3
Sesame oil 2g Sodium chloride 9g Propylene glycol 40g Phosphate buffer (0
, 1M, pH 6,0) 100ml distilled water
Total amount 1000rr! , l-coenzyme Q
1o, N1kkol HCO-60, sesame oil and half the amount of propylene glycol were mixed and dissolved by heating at about 80°C, and to this was added a solution of phosphate buffer, sodium chloride and half the amount of propylene glycol previously dissolved in distilled water. The mixture was heated to 80°C and added to make an aqueous solution having a total amount of 10,100O.

Claims (1)

[Scope of Claims] 1. A therapeutic agent for bronchial asthma containing coenzyme Q represented by the general formula (wherein n is an integer of 7 to 10) as a main component. 2. The therapeutic agent for bronchial asthma according to claim 1, wherein the coenzyme Q is coenzyme Q1o.